Gerald L. Andriole, Jr., MD, presented “Prostate Cancer Screening: Who? Why? How?” during the Jackson Hole Seminars on February 7, 2018 in Jackson Hole, Wyoming.
How to cite: Andriole, Gerald. “Prostate Cancer Screening: Who? Why? How?” February 7, 2018. Accessed Nov 2024. https://dev.grandroundsinurology.com/Prostate-Cancer-Screening-PLCO-ERSPC/
Prostate Cancer Screening: Who? Why? How?
Summary:
Gerald L. Andriole, Jr., MD, discusses the limitations and successes in the design of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSPC) trials. He also emphasizes the importance of patient selection in PSA screening and utilizing other diagnostic methods.
This is an update from Dr. Andriole’s presentation at the 2nd Annual International Prostate Cancer Update.
ABOUT THE AUTHOR
Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri.
Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed his Urology Residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a Fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland.
Dr. Andriole has over 35 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial, as well as PI of both the NIDDK Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial and the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Association, the American Association for Cancer Research, the American Society of Clinical Oncology, the American Surgical Association, the American Association of Genitourinary Surgeons, and the Clinical Society of Genitourinary Surgeons, among other societies.
